SG11201407967TA - Oligonucleotide synthesis method using highly dispersible liquid-phase support - Google Patents

Oligonucleotide synthesis method using highly dispersible liquid-phase support

Info

Publication number
SG11201407967TA
SG11201407967TA SG11201407967TA SG11201407967TA SG11201407967TA SG 11201407967T A SG11201407967T A SG 11201407967TA SG 11201407967T A SG11201407967T A SG 11201407967TA SG 11201407967T A SG11201407967T A SG 11201407967TA SG 11201407967T A SG11201407967T A SG 11201407967TA
Authority
SG
Singapore
Prior art keywords
synthesis method
acid
phase support
hydrophobic
highly dispersible
Prior art date
Application number
SG11201407967TA
Inventor
Shokaku Kim
Masanori Matsumoto
Original Assignee
Hokkaido System Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hokkaido System Science Co Ltd filed Critical Hokkaido System Science Co Ltd
Publication of SG11201407967TA publication Critical patent/SG11201407967TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C07H1/04—Introducing polyphosphoric acid radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

(i2) mwu ft iz s-5 iv x m £ titz s issaj n d9) mm IHMMi _ (41) SI5S4>!H B 2013^12^ 5 0(05.12.2013) W HRO I P CT (10) WO 2013/179412 A1 (51) C07H21/04 (2006.01) (21) PCT/JP2012/063921 (22) H|®t±J®IS: 2012 ^ 5 ^ 30 H (30.05.2012) (25) (26) @U8&M©Wi§: (71) ttiJiA ^TCDJB^HICOI^T): ItM IVXTA • X (HOKKAIDO SYSTEM SCIENCE CO., LTD.) [JP/JP]; T 0010932 it 56 it *L ffl rfi :lt E »r JN E 2 & 1 T g 2 - 1 Hokkaido (JP). (72) (75) |§0J#/tiiJ!A (SfcSICOl^TO)^): £ Sell (KIM, Shokaku) [KR/JP]; T 1838538 MBT3-8-1 HAl*^}£AIC£jftI*^l*l Tokyo (JP). S5f ® (MATSUMOTO, Masanori) [JP/JP]; T 3050817 I«|d < D 7 __ iE16-101 Ibaraki (JP). 3 < » 74 ^SA: & I<F¥?£ (THE pfi PATENT CORPORATE BODY ARUGA PATENT ^ OFFICE); T 1030013 &. E 0 AiEST 1 Tl 3§8^ tf ^ Tokyo (JP). (8i) (^ro&i^PBy > IS ft nj f b): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) *!£H (asrofci^isy > ±T(Dmm(Dfcm% 11^ nlfb): ARIPO (BW, GM, KE, GH, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), 3. — =j V T (AM, AZ, BY, KG, KZ, RU, TJ, TM), 3 — • V / ^ (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). - (&&£ 21 &(3)) (54) Title: OLIGONUCLEOTIDE SYNTHESIS METHOD USING HIGHLY DISPERSIBLE LIQUID-PHASE SUPPORT (54) ig £ P. X R 3 R 4 / = \ C—R -C—N-R —N-C-R —<\ 1 2 5 II II II NN ,^r,6, O O O v '^( OR )n (57) Abstract: Provided is a nucleic acid synthesis method, in which a highly dispersible liquid-phase support is used, a reaction can proceed in fluid (flow), a and the coupling efficiency improved. is A method for synthesizing an oligonucleotide, which comprises a step of condensing and then oxidizing nucleoside phosphoramidite compound a in the presence an acid-azole complex compound of fS using a hydrophobic-group-bound nucleoside represented by general formula (1) as a starting material, wherein the condensation re - ^ action carried out is by dissolving the hydrophobic-group-bound nucleoside or a hydrophobic-group-bound oligonucleotide and a nucleoside phosphoramidite compound in a non-polar solvent in advance and then bringing the resultant solution into contact with f— an acid-azole complex compound or a solution containing the acid-azole complex compound. (57)®$:S#Bc14jfcft£ftf*£ffll\ gfcf* (?•-) -ea>J5f&jb<nTfl|-e, ± y ?°U Tfe-Jt§3; (1) U Wt-7 J-)i x © U7|-v • SUb^&ifM^EL-TM c* =i*<7 ls*T KO)-&jSJ£-efcoT, \s*i/ KXIii®7K1tS#g-&^- Q U =i*<7 [st? R<t*<7 UT|-V 75^ Zfttm • T v /- CDn-jS)ic
SG11201407967TA 2012-05-30 2012-05-30 Oligonucleotide synthesis method using highly dispersible liquid-phase support SG11201407967TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2012/063921 WO2013179412A1 (en) 2012-05-30 2012-05-30 Oligonucleotide synthesis method using highly dispersible liquid-phase support

Publications (1)

Publication Number Publication Date
SG11201407967TA true SG11201407967TA (en) 2015-01-29

Family

ID=49672666

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407967TA SG11201407967TA (en) 2012-05-30 2012-05-30 Oligonucleotide synthesis method using highly dispersible liquid-phase support

Country Status (7)

Country Link
US (1) US9284344B2 (en)
EP (1) EP2857412B1 (en)
DK (1) DK2857412T3 (en)
IL (1) IL235978B (en)
IN (1) IN2014DN10144A (en)
SG (1) SG11201407967TA (en)
WO (1) WO2013179412A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
US8846885B2 (en) 2012-02-17 2014-09-30 Ajinomoto Co., Inc. Oligonucleotide with protected base
JP6237237B2 (en) * 2012-02-17 2017-11-29 味の素株式会社 Base protected oligonucleotide
JP6246121B2 (en) 2012-07-13 2017-12-13 株式会社新日本科学 Chiral nucleic acid adjuvant
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
JPWO2015108047A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
EP3378869A4 (en) * 2015-11-17 2019-09-18 Nissan Chemical Corporation Method for producing oligonucleotide
EP3398955A4 (en) * 2015-12-16 2019-10-16 Ajinomoto Co., Inc. Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide
JPWO2017111137A1 (en) * 2015-12-22 2018-10-18 味の素株式会社 Method for producing oligonucleotide
EP3925964A4 (en) 2019-02-15 2022-12-07 Ajinomoto Co., Inc. Production method for oligonucleotides
EP3950698A4 (en) 2019-03-28 2023-01-25 Ajinomoto Co., Inc. Method for producing oligonucleotide having phosphorothioate site
KR20220007104A (en) * 2019-05-08 2022-01-18 바이오젠 엠에이 인코포레이티드 Convergent liquid-phase synthesis of oligonucleotides
EP4006045A4 (en) * 2019-08-29 2022-10-19 FUJIFILM Corporation Nucleic acid compound manufacturing method and nucleic acid compound
JP2023520201A (en) 2020-03-31 2023-05-16 ヤンセン バイオファーマ インク． Synthesis of oligonucleotides and related compounds
FR3111896A1 (en) 2020-06-24 2021-12-31 Strainchem Synthesis processes in solution of macromolecules from units of carbohydrate derivatives
CN113583069B (en) * 2021-09-09 2023-06-06 北京大学 Nucleoside phospholipid compounds, chemical synthesis method thereof and application thereof in nucleic acid delivery
WO2024083746A1 (en) 2022-10-17 2024-04-25 Bachem Holding Ag Method and composition for oligonucleotide synthesis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094943B2 (en) * 1998-04-27 2006-08-22 Hubert Köster Solution phase biopolymer synthesis
JP2003002895A (en) * 2001-05-30 2003-01-08 Tokyo Inst Of Technol Method for synthesizing nucleic acid
JP4963665B2 (en) 2007-11-27 2012-06-27 株式会社ミツバ Flat type commutator and manufacturing method thereof
JP5548852B2 (en) * 2009-05-29 2014-07-16 国立大学法人東京農工大学 Hydrophobic group-bonded nucleoside, hydrophobic group-bonded nucleoside solution, and hydrophobic group-bonded oligonucleotide synthesis method
EP2711370B1 (en) * 2011-05-17 2018-01-03 Ajinomoto Co., Inc. Method for producing oligonucleotides
JP6237237B2 (en) * 2012-02-17 2017-11-29 味の素株式会社 Base protected oligonucleotide

Also Published As

Publication number Publication date
IL235978A0 (en) 2015-02-01
IL235978B (en) 2018-02-28
US20150112053A1 (en) 2015-04-23
EP2857412B1 (en) 2017-01-11
DK2857412T3 (en) 2017-04-03
EP2857412A4 (en) 2015-10-21
IN2014DN10144A (en) 2015-08-21
WO2013179412A1 (en) 2013-12-05
US9284344B2 (en) 2016-03-15
EP2857412A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
SG11201407967TA (en) Oligonucleotide synthesis method using highly dispersible liquid-phase support
SG11201808721YA (en) Cell-free production of ribonucleic acid
SG11201900635QA (en) Chimeric antigen receptors targeting bcma and methods of use thereof
SG11201903480TA (en) Cell culture device system and methods of use thereof
SG11201809522WA (en) Method of nucleic acid sequence determination
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909710XA (en) Indole ahr inhibitors and uses thereof
SG11201807069XA (en) Nucleic acid sequencing method and system employing enhanced detection of nucleotide-specific ternary complex formation
SG11201806400XA (en) Replicative transposon system
SG11201408297XA (en) Porous graphene oxide materials
SG11201804997XA (en) Process for preparing non-cariogenic, sustained energy release juice
SG11201901077RA (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
SG11201803169WA (en) Cellulase variants and polynucleotides encoding same
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201903182XA (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201808457PA (en) Icos ligand variant immunomodulatory proteins and uses thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201811149TA (en) METABOLIC DRUG LOADING OF EVs
SG11201404936YA (en) Channel plate heat transfer system
SG11201908899WA (en) An alcoholic beverage
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201407540TA (en) Methods of growing uniform, large-scale, multilayer graphene films